Styx: Blades of Greed is already shaping up to be a memorable third entry to cap off the Styx trilogy, and hopefully it will ...
Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback